Ocular Therapeutix, Inc. (OCUL)
8.91
+0.15
(+1.71%)
USD |
NASDAQ |
Apr 15, 16:00
8.94
+0.03
(+0.34%)
After-Hours: 20:00
Ocular Therapeutix Research and Development Expense (Annual) : 197.10M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| EyePoint Plc | 221.04M |
| Regeneron Pharmaceuticals, Inc. | 5.306B |
| Vertex Pharmaceuticals, Inc. | 3.754B |
| ACADIA Pharmaceuticals, Inc. | 328.80M |
| Rhythm Pharmaceuticals, Inc. | 166.90M |